EXEL vs TVTX
Exelixis vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TVTX
Travere Therapeutics, Inc.
62
Buy
| Metric | EXEL | TVTX |
|---|
| AI Score |
67
|
62
|
| Price |
$51.30
|
$60.25
|
| P/E Ratio |
15.60×
|
-133.80×
|
| ROE |
36.2%
|
-22.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
94.4%
|
| Debt / Equity |
0.09×
|
25.16×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
59.0
|
| Beta |
0.422
|
1.042
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TVTX.
EXEL leads by 5 points.
EXEL scores 67/100 (Buy) versus TVTX at 62/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TVTX Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Bollinger bandwidth of 17.2% signals elevated volatility — Risk